GlassScriptPhysician profile
Daniel Christian Corry
NPI 1760037816
$9,705.60
in general payments reported to CMS, 2019-2025
21 companies · $921 in 2025
The $921 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,036 · 2022: $3,106 · 2023: $2,252 · 2024: $2,391 · 2025: $921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,715 · Travel and Lodging: $1,849.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,715.26 |
| Travel and Lodging | $1,848.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,477.40 | 2021-2025 | General - Therapies, Artisan, Intracept |
| Nevro Corp. | $1,921.75 | 2022-2023 | Senza |
| Relievant Medsystems, INC. | $1,385.01 | 2022-2023 | Intracept |
| Biohaven Pharmaceuticals, INC. | $840.43 | 2021 | |
| Painteq LLC | $739.26 | 2022-2024 | Painteq |
| Medtronic, INC. | $517.41 | 2021-2024 | Intellis Adaptivestim, Kyphon Express II Kyphopak Tray, Aquamantys(Tm) |
| Abbvie INC. | $487.59 | 2022-2025 | |
| Pfizer INC. | $306.37 | 2021-2025 | |
| Mml US, INC. | $201.97 | 2024-2025 | Reactiv8 |
| Lundbeck LLC | $189.99 | 2023-2025 | Vyepti |
| Spr Therapeutics, INC | $138.79 | 2023-2025 | Sprint Pns System |
| Biohaven Pharmaceutical Holding Company LTD. | $103.49 | 2022 | |
| Nalu Medical, INC. | $96.73 | 2021-2025 | Nalu Neurostimulation System |
| Allergan, INC. | $79.37 | 2021-2022 | |
| Grt US Holding, INC. | $51.72 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $42.84 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $38.24 | 2022 | |
| Bioventus LLC | $31.60 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.46 | 2025 | |
| Acacia Pharma INC | $19.43 | 2021 | |
| Averitas Pharma INC. | $16.75 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Corry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.